Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Barratt

Showing results (31-40 of 272) with videos related to

Pageof 28
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 1, 2024
The use of albuminuria or proteinuria for risk prediction in IgANChee Kay Cheung, Jonathan Barratt
American Journal of Nephrology|February 28, 2019
Pregnancy in IgA Nephropathy: An Effect on Renal Outcome?Chee Kay Cheung, Jonathan Barratt
Kidney International|December 1, 2010
Immune complex formation in IgA nephropathy: CD89 a 'saint' or a 'sinner'?Joanna K Boyd, Jonathan Barratt
Clinical Journal of the American Society of Nephrology : CJASN|October 9, 2019
Biomarkers to Predict Progression in IgA NephropathyChee Kay Cheung, Jonathan Barratt
Kidney International|April 21, 2023
The authors replyJonathan Barratt, Brad H Rovin,
Kidney International|March 22, 2023
First do no harm: systemic glucocorticoids should not be used for the treatment of progressive IgA nephropathyChee Kay Cheung, Jonathan Barratt
Clinical Kidney Journal|December 6, 2023
The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathySee Cheng Yeo, Jonathan Barratt
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 23, 2026
Hematuria as a biomarker guiding treatment decisions in IgA nephropathy? noChee Kay Cheung, Jonathan Barratt
The New England Journal of Medicine|April 10, 2024
Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. ReplyMohit Mathur, Jonathan Barratt, Yusuke Suzuki
Journal of the American Society of Nephrology : JASN|March 17, 2026
Is It Time to Review How We Use Proteinuria to Define Disease Activity in Glomerular Diseases?Fadi Fakhouri, Eva Jenny, Jonathan Barratt
Pageof 28

Showing results (31-40 of 272) with videos related to

Sort By:
Pageof 28
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 1, 2024
The use of albuminuria or proteinuria for risk prediction in IgANChee Kay Cheung, Jonathan Barratt
American Journal of Nephrology|February 28, 2019
Pregnancy in IgA Nephropathy: An Effect on Renal Outcome?Chee Kay Cheung, Jonathan Barratt
Kidney International|December 1, 2010
Immune complex formation in IgA nephropathy: CD89 a 'saint' or a 'sinner'?Joanna K Boyd, Jonathan Barratt
Clinical Journal of the American Society of Nephrology : CJASN|October 9, 2019
Biomarkers to Predict Progression in IgA NephropathyChee Kay Cheung, Jonathan Barratt
Kidney International|April 21, 2023
The authors replyJonathan Barratt, Brad H Rovin,
Kidney International|March 22, 2023
First do no harm: systemic glucocorticoids should not be used for the treatment of progressive IgA nephropathyChee Kay Cheung, Jonathan Barratt
Clinical Kidney Journal|December 6, 2023
The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathySee Cheng Yeo, Jonathan Barratt
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 23, 2026
Hematuria as a biomarker guiding treatment decisions in IgA nephropathy? noChee Kay Cheung, Jonathan Barratt
The New England Journal of Medicine|April 10, 2024
Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. ReplyMohit Mathur, Jonathan Barratt, Yusuke Suzuki
Journal of the American Society of Nephrology : JASN|March 17, 2026
Is It Time to Review How We Use Proteinuria to Define Disease Activity in Glomerular Diseases?Fadi Fakhouri, Eva Jenny, Jonathan Barratt
Pageof 28